Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

85.39 -0.94 (-1.08%)

Streaming Delayed Price Updated: 10:05 AM EDT, Jul 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	150,865
Open	85.56
Bid (Size)	85.27 (100)
Ask (Size)	85.52 (500)
Prev. Close	86.33
Today's Range	85.30 - 86.74
52wk Range	40.03 - 86.74
Shares Outstanding	141,797,854
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

July 06, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

June 25, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	+7.2%	+7.2%
1 Month	+16.1%	+16.1%
3 Month	+15.6%	+15.6%
6 Month	+4.8%	+4.8%
1 Year	+104.4%	+104.4%

More News

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

June 24, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Surge After Crushing Q1 Estimates and Raising Full-Year Guidance ↗

April 29, 2026

Via Chartmill

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗

June 19, 2026

Via InvestorPlace

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

June 08, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

June 04, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

Via The Motley Fool

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

May 28, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗

May 25, 2026

Via MarketBeat

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference ↗

May 18, 2026

Via MarketBeat

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease

May 14, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to host 2026 virtual Annual Meeting of Stockholders

May 04, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

May 01, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis (IONS) Q1 2026 Earnings Call Transcript ↗

April 29, 2026

Via The Motley Fool

Ionis reports first quarter 2026 financial results and highlights progress on key programs

April 29, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

April 28, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis (IONS) Q4 2025 Earnings Transcript ↗

April 21, 2026

Via The Motley Fool

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

April 21, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to hold first quarter 2026 financial results webcast

April 15, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

Via MarketMinute

When Insider Selling Is a Good Thing: 2 Stocks to Watch ↗

March 23, 2026

Via MarketBeat

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

March 23, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

Via The Motley Fool

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

Via The Motley Fool

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?

Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market

What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?

The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 85.39

When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 07/08/26 10:05 AM ET

What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 12.11B

How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?

Ionis Pharmaceuticals, Inc. - Common Stock has 12B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.